申请人:Jia Wei
公开号:US10441564B2
公开(公告)日:2019-10-15
The present invention provides a fructose analogue and a composition thereof which can be used for cancer treatment, has a targeting effect and has little effect on normal cells, particularly when used in the treatment of acute myeloid leukemia (‘AML’) and pancreatic cancer and other types of cancer having similar metabolic characteristics. In the present invention, the fructose analog is selected from the group consisting of 2,5-anhydro-D-mannitol and the 2,5-anhydro-D-mannitol derivative substituted at the 1-position or 6-position by an amino group, an alkyl group or an aryl group, anhydro-D-mannitol tetraacetate and 2,5-anhydroglucitol and the like. The fructose analogs of the present invention can be used to prepare and treat cancer drugs and can be prepared as injectable preparations or oral preparations. The fructose analogues of the present invention can be used in combination with conventional anticancer drugs when used in the preparation of a medicament for the treatment of cancer. The fructose analogs of the present invention can be used in combination with glucose analogues in the treatment of cancer or organ fibrosis.
本发明提供了一种果糖类似物及其组合物,可用于癌症治疗,具有靶向作用,对正常细胞影响小,尤其是用于治疗急性髓性白血病("AML")和胰腺癌以及具有类似代谢特征的其他类型癌症时。在本发明中,果糖类似物选自 2,5-脱水-D-甘露醇和在 1 位或 6 位被氨基、烷基或芳基取代的 2,5-脱水-D-甘露醇衍生物、脱水-D-甘露醇四乙酸酯和 2,5-脱水葡萄糖醇等组成的组。本发明的果糖类似物可用于制备和治疗癌症药物,可以制备成注射制剂或口服制剂。在制备治疗癌症的药物时,本发明的果糖类似物可与常规抗癌药物联合使用。本发明的果糖类似物可与葡萄糖类似物联合用于治疗癌症或器官纤维化。